ArticleDrug design, development and therapy2026
Development of Membrane-Targeting Cannabigerol Derivatives as Potent Broad-Spectrum Antibacterial Agents.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This research aimed to develop novel membrane-targeting antibacterial agents via rational design and synthesis of hybrid compounds derived from cannabigerol (CBG) and antimicrobial peptide (AMP) motifs. This approach targeted key limitations of CBG, specifically its poor aqueous solubility, restricted activity against Gram-negative pathogens, and low bioavailability. By incorporating AMP domains, we intended to exploit their membrane-disruptive capability, thereby achieving enhanced broad-spectrum activity, diminished propensity for resistance, and improved pharmacological properties. Methods: A library of membrane-active cannabigerol derivatives was designed and synthesized through conjugation of antimicrobial peptides structural motifs to the cannabigerol core scaffold by a flexible chemical linker. All compounds were characterized by Results: The compound Conclusion: Compound
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.